

Costa Rican Research Center on Surgery and Cancer



Bridging the gap between basic and applied cancer research

Prof. Dr. Rodrigo Mora, Ph.D.
Director CICICA-UCR

Ricardo Chinchilla
Ph.D. candidate

Ana Cristina Castro
Ph.D candidate

CICICA

Centro de
**Investigación en
Cirugía y Cáncer**




**UNIVERSIDAD DE
COSTA RICA**

World


Source: Globocan 2020



Number of new cases in 2020, both sexes, all ages



Number of deaths in 2020, both sexes, all ages



Geography



Numbers at a glance

Total population

7 794 798 844

Number of new cases

19 292 789



Number of deaths

9 958 133

Number of prevalent cases (5-year)

50 550 287

2 The global cancer burden is significant and increasing




Physical, emotional and financial burden for individuals, their families, communities, health systems and governments

Costa Rica

Source: Globocan 2020




Number of new cases in 2020, males, all ages



Geography



Number of new cases in 2020, females, all ages



Numbers at a glance

Total population

5 094 114

Number of new cases

13 139

Number of deaths


6 028

Number of prevalent cases (5-year)

35 534


Cancer in Costa Rica

Estimated number of deaths from 2020 to 2040, Both sexes, age [0-85+]
Costa Rica



Spectrum of cancer control interventions

Figure 1.1. Interventions along the cancer continuum and examples of levels of care.



WHO: prioritize in prevention and early diagnosis

Research Center on Surgery and Cancer


(Inaugurated in February 2023)

Interdisciplinary unit dedicated to basic and applied research on surgery and cancer
(Interdisciplinary: health sciences, basic sciences, veterinary medicine, engineering, ...)



Focus on research, development and implementation of new strategies and methodologies for cancer prevention, early diagnosis and precision oncology

Translational medicine perspective approach



Big role of patient advocates!

Combining the findings from basic-, applied- and clinical research to build upon and inform each other, in order to develop projects that translate into a significant, positive impact on the population's health..

Research Center facilities



- Specialized clinic for early cancer diagnosis and precision oncology
- Program on continued education and training on minimally invasive surgery
- Specialized laboratory for early cancer diagnosis and precision oncology

1) Specialized clinic for early cancer diagnosis and precision oncology

- Medical care models for early detection and diagnosis of cancer
- Intended to tackle the most relevant cancers in our country
(prostate, testicle, cervix, ovary, breast, oropharynx, thyroid, esophagus, stomach, colorectum, liver, bile duct, pancreas)
- Medical offices staffed by medical specialists in gynecologic oncology, urology, head and neck, thyroid cancer, etc & Endoscopy unit for Gastroenterology
- Partnership with civil society cancer organizations Foro permanente de Cáncer en Mujeres de Costa Rica
- Specific agreements with the Costa Rican Social Security Fund (aka CCSS)(which is responsible for the public universal health care system of our country)



Specialists at CICICA



Dr. Angie Mora, Gynecology-Oncology



Dr. Gonzalo Azua, Urologist


2) Program on continued education and training on minimally invasive surgery

Training process through:

- simulation (**Laparoscopic Simulators**)
- practice in an *in vivo* model in a controlled surgical environment (**Operating Room**)

Aimed at

- **medical specialists**
- **postgraduate students in medical specialties (residents) in the surgical area**
- **postgraduate students in surgical nursing**



Development of complex surgical skills

Continued education and training on:

- Laparoscopy (basic, intermediate, advanced)
- Microsurgery
- Laparoscopic surgical instrumentation
- Specific advanced laparoscopy courses



Dr. Marco Zúñiga, Specialist in Non-Invasive Surgery



Dr. Jilma Alemán, Veterinarian

3) Specialized laboratory for early cancer diagnosis and precision oncology

- Establishment of cellular, molecular, immunological and pathological laboratory tests for precision oncology

Precision oncology: an approach that takes into account differences in each person's genes, environment, and lifestyles to tailor cancer prevention and treatment.

- Clinical research projects*

Projects on new diagnostic tools in cancer

*Adherence to national and international clinical research law and regulations, and ethical review boards.


Drug bioequivalence studies

Early cancer screening in a high risk population for colon and gastric cancer.



- Facilities under one roof:

- Cell culture
 - Clinical pathology
 - Molecular biology
 - Flow cytometry
 - Image flow cytometry
 - Next generation sequencing (NGS)
 - Single-cell sequencing
 - Circulating tumor DNA (ctDNA) and Circulating Tumor Cells (CTCs)
-
- Basic and applied research projects
 - Research core facility
 - Diagnostic services for cancer



Ricardo
Chinchilla
Microbiologist



Ana Cristina
Microbiologist



Jad Abaas,
Pathologist



Basic Research

Mechanisms of tumor chemosensitivity

- Late biological responses to pulsed - low dose genotoxic chemotherapeutic agents.
- Gene dosage compensation in a model of accelerated genomic instability

Oncoimmunology


- Tumor-specific T cell receptors as a therapeutic application against cancer.
- Modulation of immunogenic cell death and effect on bystander cells.
- Chemokine interaction network and predictive models of chemotatic effect.

Tumor microenvironment

- Role of *Helicobacter pylori* in the microenvironment that supports the emergence of gastric cancer.
- Research platform for the epidemiology and biology of colorectal cancer in Costa Rica.

Systems Biology of Cancer

- Gene dosage compensation in aneuploid cancer.
- Bistability in Macrophage Polarization.
- miRNA-based therapeutics.



Dr. Steve Quirós, Ph.D.



Dr. Isaac Quirós, Ph.D.



Dr. Javier Mora, Ph.D.



Dr. Warner Alpízar, Ph.D.




Dr. Rodrigo Mora, Ph.D.

Targeting Gene dosage compensation in aneuploid cancer

iScience



Available online 8 November 2021, 103407

In Press, Journal Pre-proof ?



Article

MYC dosage compensation is mediated by miRNA-transcription factor interactions in aneuploid cancer



Received: 24 April 2023 | Revised: 31 October 2023 | Accepted: 7 November 2023

DOI: 10.1002/cam4.6719

REVIEW

Cancer Medicine Open Access WILEY

Gene dosage compensation: Origins, criteria to identify compensated genes, and mechanisms including sensor loops as an emerging systems-level property in cancer

Diana M. Bravo-Estupián^{1,2,3,4} | Karol Aguilar-Guerrero^{1,5} | Steve Quirós^{1,6} | Man-Sai Acón¹ | Christian Marín-Müller⁴ | Miguel Ibáñez-Hernández³ | Rodrigo A. Mora-Rodríguez^{1,6}

Translational Research and implementation of novel diagnostics

- Diagnostic tests in anatomical and clinical pathology

Image Analysis and Machine learning

- Diagnostic test development and implementation


e.g. detection of HPV malignant transformation and image based assays

- Genetic testing for hereditary cancer predisposition syndromes & for somatic variants or mutations in tumors & Pharmacogenomics

- Liquid biopsy (ctDNA and CTCs) and exome sequencing

e.g. ctDNA and CTCs as a predictor of response to treatment in breast cancer

- Prospective OncoSeek study on a high risk population for Colon and Gastric Cancer.



Translational genomic research on genetic biomarkers in Liquid Biopsy



Dr. Ricardo Chinchilla, M.Sc.



UNIVERSIDAD DE
COSTA RICA

CICICA


Centro de
Investigación en
Cirugía y Cáncer

• Genetic biomarkers of Circulating Tumor DNA for Monitoring Breast Cancer Patients in Costa Rica


- Prospective study: 1 to 4 blood samples
- cfDNA concentration
- SNVs:
 - *ESR1*: Y537N, Y537S, Y537C y D538G
 - *PIK3CA*: E545K, H1047L




Dr. Allan Ramos PhD.




Results



cfDNA in breast cancer subtypes




Overall Survival Probability according to cfDNA






- Dynamic levels of ctDNA and CTCs as a predictor of response or failure to combined therapy with Trastuzumab, Pertuzumab and Taxanes, in HER2-positive metastatic breast cancer from January 2024 to December 2026, in the Medical Oncology Services of San Juan de Dios, México, Calderón Guardia and San Vicente de Paúl Hospitals.







- Protein biomarkers and analysis of images of circulating tumor cells (CTCs) in blood samples from patients with metastatic breast cancer.



- Reference intervals for various biomarkers of circulating DNA in the Costa Rican in the Costa Rican population (IRAC Project)






- Expression profile of microRNAs in paraffin-embedded tissue biopsies from breast cancer patients at Calderón Guardia Hospital during a one-year period.



- Regulatory networks in the progression of ductal carcinoma in situ (DCIS) to invasive breast cancer (IBC).

BioNetUCR



Translational cell biology research on image-enhanced cytology for cervical cancer




Dr. Ana Cristina Castro, M.Sc.

DIAGNOSTIC TESTING FOR CERVICAL CANCER

HPV ONCOTECT™

Human Papilloma Virus (HPV)


- Low risk HPV
- High risk HPV
 - Enters the cervical cells and has the capacity to cause carcinogenesis.



Cervical cancer




- 1st cause of death for women younger than 35 yo
- Mortality in low and middle income countries is 3x higher
- Worldwide a woman dies every **2 min**



- 4th cause of incidence and mortality due to cancer in women
- **320 cases per year with 140 deaths**




(and pathologies related to HPV)



Thousands of women are diagnosed with the viral infection but with high probability of spontaneous regression (virus elimination)


Detection is not the
same as cancer

Triage and screening diagnostic tests



Pap

Bad sensitivity



Biopsy

Bad predictor of
the disease!



Genotypes (hrHPV)

Low clinical
sensitivity/specificity


Screening

should have high sensitivity

Triage

should have high specificity


What can we do?




- Identifies high risk HPV (diagnosis and follow-up)
- High sensitivity and specificity with high predictive value (no unnecessary alerts)
- Well-known sample collection




Patients samples




Flow cytometry



Validated test



Data analysis




Automation and
Machine Learning

Our solution

for a secondary triage

Implementation of a test for malignant transformation in CR

The answer could be in the biology of the virus in order to distinguish between infection and transformation









Observation of flow
cytometry on images
includes mRNA
signals




What we
can obtain

P06190_5featuresCh11.daf


Population: R10_Positives & SingleCells & R2 & R1 View: Composite Order By... Object Number



How does classification work?




Flow cytometry images



Multiple examples of labeled cells




Disease pattern recognition




Pattern recognition algorithms

Images of single cells have lots of features for classifiers




Data from images of individual cells allow classification

- For the first time, a lab has annotations of individual cells from clinical samples.
- Supervised learning from information of texture/morphology from other channels of fluorescence/bright field .



Data from images of individual cells allow classification

- Positive examples vs negative examples from the same clinical sample
- Feature ranking
- Building of a classifier independent from proba labeling.
- Very low cost of basic stainings!!



Research Center on Surgery and Cancer

CICICA

Centro de
Investigación en
Cirugía y Cáncer



**UNIVERSIDAD DE
COSTA RICA**



5% of World's biodiversity in 51100 Km²

<https://cicica.ucr.ac.cr/> cicica@ucr.ac.cr rodrigo.morarodriguez@ucr.ac.cr